Hypermethylation of SHOX2 and RASSF1A in intraoperative pleural lavage fluid as a molecular signature of aggressive tumor biology and high histologic grade in stage I lung adenocarcinoma [0.03%]
I期肺腺癌术中胸膜灌洗液中SHOX2和RASSF1A高甲基化作为侵袭性肿瘤生物学和组织学分级高的分子标志物
Yufei Zhang,Liang Chen,Wenjun Dai et al.
Yufei Zhang et al.
Backgrounds: DNA methylation profiling has emerged as a powerful adjunct for refining pathological accuracy. This study investigates the correlation between the SHOX2 and RASSF1A methylation status in intraoperative pleur...
18F-FDG PET/CT and receptor-positive circulating tumor cells-based machine learning model for predicting poorly differentiated lung adenocarcinoma [0.03%]
基于18F-FDG PET/CT和受体阳性循环肿瘤细胞的机器学习模型预测肺腺癌分化程度差
Yi Li,Feng-Xian Zhang,Wen-Long Zhang et al.
Yi Li et al.
Introduction: This study aimed to develop and validate a machine learning model that integrates radiomic features from 2-[18F]fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) wi...
Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort [0.03%]
不可切除的III期EGFR突变型NSCLC患者在接受确定性化疗和放疗后的奥希替尼治疗：LAURA中国亚组研究结果
Xiaorong Dong,Hong Jian,Meijuan Huang et al.
Xiaorong Dong et al.
Background: In the phase III LAURA study, osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor demonstrated statistically significant improvement in progression-free survival (...
Real-world comparative effectiveness of atezolizumab versus durvalumab for extensive-stage small-cell lung cancer [0.03%]
阿特朱单抗与度伐鲁单抗治疗广泛期小细胞肺癌的真实世界有效性比较研究
Tomoiki Aiba,Shuichiro Hara,Shinichiro Tominaga et al.
Tomoiki Aiba et al.
Background: Both atezolizumab and durvalumab combined with platinum-etoposide have become standard first-line treatments for extensive-stage small-cell lung cancer (ES-SCLC), yet head-to-head real-world comparative data r...
The emerging role for induction chemoimmunotherapy in unresectable stage III NSCLC: A promising approach in need of a definitive phase III trial [0.03%]
不可切除的III期NSCLC中诱导化免疫疗法的作用及展望：一个值得开展的确证性III期临床试验方向
Andrew J Piper-Vallillo,Henry S Park
Andrew J Piper-Vallillo
Real-world outcomes of pembrolizumab-chemotherapy combination in metastatic non-small cell lung cancer by age and sex: A national population-based study [0.03%]
帕博利珠单抗联合化疗治疗转移性非小细胞肺癌的现实世界结局：按年龄和性别分层的全国人群基于研究
Chin Hang Yiu,Stephen J Clarke,Christine Y Lu
Chin Hang Yiu
Introduction: Lung cancer is the leading cause of cancer-related mortality worldwide. Immune checkpoint inhibitors (ICIs) are standard first-line therapy for metastatic non-small cell lung cancer (NSCLC), but real-world o...
Family history enrichment in Non-Small cell Lung Cancer: A cross-sectional - prospective study to inform referral for germline testing [0.03%]
非小细胞肺癌家系史扩充的横断面-前瞻性研究：为进一步开展胚系检测工作提供信息
Fabrizio Citarella,Francesco M Venanzi,Giulia Di Giovanni et al.
Fabrizio Citarella et al.
Background: Family history of cancer (FHC) is a recognized proxy of inherited cancer susceptibility. In NSCLC, however, the clinical relevance of FHC remains poorly defined, and standardized approaches to identify patient...
Outcomes and toxicities of immune checkpoint inhibitors in patients with lung cancer and pre-existing autoimmune disease [0.03%]
自身免疫性疾病患者接受免疫检查点抑制剂治疗的疗效及毒性反应
Siddhartha Goutam,Arjun A Raghavan,Hans Alday et al.
Siddhartha Goutam et al.
Background: Patients with pre-existing autoimmune disease (PAD) are often excluded from immune checkpoint inhibitor (ICI) clinical trials in thoracic oncology, creating uncertainty regarding their real-world safety and ef...
Lack of impact of antibiotics and proton pump inhibitors on the efficacy of preoperative chemoimmunotherapy in locally advanced non-small cell lung cancer: A multicenter retrospective study [0.03%]
抗生素和质子泵抑制剂不会影响局部晚期非小细胞肺癌新辅助化疗免疫治疗的疗效：一项多中心回顾性研究
Michihito Toda,Kazuki Takada,Kotaro Nomura et al.
Michihito Toda et al.
Introduction: Antibiotics and proton pump inhibitors (PPIs) have been associated with the reduced efficacy of immune checkpoint inhibitor (ICI) in patients with advanced non-small cell lung cancer (NSCLC). This study asse...
Comparative clinical utility of the 2024 Fleischner Society updated glossary versus traditional classifications for pulmonary subsolid nodules [0.03%]
2024年Fleischner学会更新词典与传统分类在肺部亚实性结节临床应用中的比较效用
Fenglan Li,Linlin Qi,Dilinaer Wusiman et al.
Fenglan Li et al.
Background: Current pulmonary subsolid nodules (SSNs) classifications remain controversial in terms of interobserver agreement and predictability of pathological subtypes and prognosis. The 2024 Fleischner Society updated...